Hypoglycemia is the most common metabolic disorder of the newborn, and the only known common preventable cause of brain damage in newborn babies. However, the best approach to diagnosis and management remains unclear. One major challenge is that the blood glucose concentration at which brain damage is incurred may differ in different babies, and it is not known how low, how often, or for how long low blood glucose concentrations must occur before brain damage occurs. There have been calls, including from the NICHD1, for large follow-up studies of children in whom glucose concentrations were measured in the newborn period and encompassed a range wide enough to determine relationships between glucose concentrations and later outcome. This proposal is to conduct just such a study. Our hypothesis is that developmental performance in early childhood is related to the severity, duration and frequency of low glucose concentrations in the first week after birth.
The specific aims are to determine: 1. Whether the severity, duration and frequency of low glucose concentrations recorded in the first week after birth are related to clinical and developmental outcomes at 2 and 4.5 years of age. 2. Whether these relationships differ in babies with different risk factors or perinatal histories. 3. What glucose concentrations provide the best discriminatory definition for """"""""low"""""""" in relation to these outcomes in different groups of babies, and thus may provide an evidence-based threshold for intervention. A cohort of <500 term and late preterm babies (e35 weeks) is being recruited. All are at risk of neonatal hypoglycemia, and are managed according to current clinical guidelines. All babies also have continuous interstitial glucose monitoring for at least 48 h and up to 7 d after birth. Data from these monitors are not used for clinical management, but do provide valuable information about the severity, duration and frequency of low glucose concentrations. Approximately 40% of the babies develop hypoglycemia, clinically defined as a blood glucose concentration <2.6mM, and are therefore treated. However, a further 20-30% experience episodes of interstitial glucose concentrations <2.6mM that are not detected clinically and therefore are not treated. Children of consenting parents will be assessed at 2 and 4.5 years of age. The assessments will include standardised measures of growth, neurological function, vision, cognitive and language development, memory, executive function, general health and family environment. Data analysis will include multivariate modelling to assess the relationships between neonatal glucose concentrations and developmental outcomes, with appropriate adjustment for perinatal events and potential postnatal family and environmental influences. Results will provide a much-needed evidence base to inform clinical practice in the short term, while also providing the critical evidence base upon which randomized trials of appropriate interventions can be designed.

Public Health Relevance

A low blood sugar level (hypoglycemia) is common in newborn babies, and sometimes causes brain damage;however it is not known which babies will suffer brain damage or at what blood sugar levels this will occur. This study will assess development of pre-school children who experienced hypoglycemia as newborns. The results will help provide critical information about how sugar levels in newborn babies should be monitored and managed to prevent brain damage while at the same time minimising unneccessary testing and treatment, thereby reducing both the number of children with intellectual disabilities and the cost of their neonatal care.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
1R01HD069622-01
Application #
8156704
Study Section
Developmental Brain Disorders Study Section (DBD)
Program Officer
Raju, Tonse N
Project Start
2011-08-15
Project End
2016-07-31
Budget Start
2011-08-15
Budget End
2012-07-31
Support Year
1
Fiscal Year
2011
Total Cost
$359,075
Indirect Cost
Name
University of Auckland
Department
Type
DUNS #
590330247
City
Auckland
State
Country
New Zealand
Zip Code
1010
Goodman, Lucy; Chakraborty, Arijit; Paudel, Nabin et al. (2017) Vision screening at two years does not reduce the prevalence of reduced vision at four and a half years of age. Clin Exp Optom :
Thompson, Benjamin; McKinlay, Christopher J D; Chakraborty, Arijit et al. (2017) Global motion perception is associated with motor function in 2-year-old children. Neurosci Lett 658:177-181
Paudel, Nabin; Chakraborty, Arijit; Anstice, Nicola et al. (2017) Neonatal Hypoglycaemia and Visual Development: A Review. Neonatology 112:47-52
Chakraborty, Arijit; Anstice, Nicola S; Jacobs, Robert J et al. (2017) Global motion perception is related to motor function in 4.5-year-old children born at risk of abnormal development. Vision Res 135:16-25
Harding, J E; Harris, D L; Hegarty, J E et al. (2017) Corrigendum to ""An emerging evidence base for the management of neonatal hypoglycemia"" [Early Hum. Dev. 2017; 104: 51-56]. Early Hum Dev 108:61
Harding, Jane E; Harris, Deborah L; Hegarty, Joanne E et al. (2017) An emerging evidence base for the management of neonatal hypoglycaemia. Early Hum Dev 104:51-56
Burakevych, Nataliia; Mckinlay, Christopher Joel Dorman; Alsweiler, Jane Marie et al. (2017) Bayley-III motor scale and neurological examination at 2 years do not predict motor skills at 4.5 years. Dev Med Child Neurol 59:216-223
Harris, Deborah L; Alsweiler, Jane M; Ansell, Judith M et al. (2016) Outcome at 2 Years after Dextrose Gel Treatment for Neonatal Hypoglycemia: Follow-Up of a Randomized Trial. J Pediatr 170:54-9.e1-2
Burakevych, Nataliia; McKinlay, Christopher Joel Dorman; Alsweiler, Jane Marie et al. (2016) Pre-school screening for developmental and emotional health: Comparison with neurodevelopmental assessment. J Paediatr Child Health 52:600-7
McKinlay, Christopher J D; Alsweiler, Jane M; Ansell, Judith M et al. (2015) Neonatal Glycemia and Neurodevelopmental Outcomes at 2 Years. N Engl J Med 373:1507-18

Showing the most recent 10 out of 16 publications